PC
Paul Capital
Private EquityActivePaul Capital provides creative liquidity solutions for direct investments.
Central, Hong KongFounded 2012
10
Investments
8
Exits
$2.5B
AUM
80.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Paul Capital.
Investment Thesis & Strategy
Paul Capital invests in fintech, life science, and venture capital companies across various stages, providing creative liquidity solutions for direct investments.
Investment Activity
Deals per year over the last 5 years
8
20041
20050
20060
20071
2008Portfolio Companies
Selected investments from their portfolio of 10 companies
P
Pharmacyclics
Biotech · Growth, 2008
J
Jazz Pharmaceuticals
Biotech · Growth, 2005
V
ViroPharma
Biotech · Growth, 2004
C
Cubist Pharmaceuticals
Biotech · Growth, 2004
S
Sepracor
Biotech · Growth, 2004
G
Gilead Sciences
Biotech · Growth, 2004
C
Celgene
Biotech · Growth, 2004
M
Medivation
Biotech · Growth, 2004
A
Amgen
Biotech · Growth, 2004
S
Seattle Genetics
Biotech · Growth, 2004
Notable Exits
CompanyTypeYearValue / Acquirer
Portola PharmaceuticalsAcquisition2020$1.2B
MedivationAcquisition2016$14B
NPS PharmaceuticalsAcquisition2014$5.2B
PharmacyclicsIPO2013—
Onyx PharmaceuticalsAcquisition2013$10.4B
MedImmuneAcquisition2007$15.6B
Jazz PharmaceuticalsIPO2004—
Seattle GeneticsIPO2001—
Frequently Asked Questions
Paul Capital focuses on Series B, Series C+ stage investments.
Related Investors
CCB International
Central, Hong Kong · 38 deals
BlackPine
Central, Hong Kong · 20 deals
FountainVest Partners
Central, Hong Kong · 13 deals
Bank of China Group Investment
Central, Hong Kong · 6 deals
China Orient Asset Management (International) Holding
Central, Hong Kong · 5 deals
Tree Line Asia
Central, Hong Kong · 5 deals